ID: ALA230286

Max Phase: Preclinical

Molecular Formula: C25H24N8O2

Molecular Weight: 468.52

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(NC(=O)c2ccc(N=NN(C)CO)cc2)cc1Nc1nccc(-c2cccnc2)n1

Standard InChI:  InChI=1S/C25H24N8O2/c1-17-5-8-21(28-24(35)18-6-9-20(10-7-18)31-32-33(2)16-34)14-23(17)30-25-27-13-11-22(29-25)19-4-3-12-26-15-19/h3-15,34H,16H2,1-2H3,(H,28,35)(H,27,29,30)

Standard InChI Key:  CRNMRKUVIVTISX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 468.52

Molecular Weight (Monoisotopic): 468.2022

AlogP: 4.72

#Rotatable Bonds: 8

Polar Surface Area: 127.99

Molecular Species: NEUTRAL

HBA: 8

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.64

CX Basic pKa: 4.26

CX LogP: 4.40

CX LogD: 4.40

Aromatic Rings: 4

Heavy Atoms: 35

QED Weighted: 0.19

Np Likeness Score: -1.58

References

1. Rachid Z, Katsoulas A, Brahimi F, Jean-Claude BJ..  (2003)  Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase.,  13  (19): [PMID:12951113] [10.1016/s0960-894x(03)00553-5]

2. Rachid Z, Katsoulas A, Williams C, Larroque AL, McNamee J, Jean-Claude BJ..  (2007)  Optimization of novel combi-molecules: identification of balanced and mixed bcr-abl/DNA targeting properties.,  17  (15): [PMID:17572088] [10.1016/j.bmcl.2007.05.067]

3. Cui J, Fu R, Zhou LH, Chen SP, Li GW, Qian SX, Liu S..  (2013)  BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives.,  23  (8): [PMID:23473682] [10.1016/j.bmcl.2013.01.113]

Source

Source(1):

• Scientific Literature